Retail Giants and Pharma Stocks Soar to New Highs Amid Strong Earnings and Optimism

Shares of Target Corp. (TGT), Merck & Co Inc. (MRK), and Charles Schwab Corp. (SCHW) reached new highs last week, driven by a combination of strong earnings results, positive clinical trial momentum, and Wall Street optimism.

TGT stock surged 4.5% on Friday after multiple analysts hiked their price targets following the company's second-quarter (Q2) earnings report. The retail chain posted adjusted earnings per share of $2.46 on $26.54 billion in revenue, beating analyst consensus estimates.

Joseph Feldman from Telsey Advisory raised the price target on Target to $182 from $170 and maintained an 'Outperform' rating, citing the company's transformation progress. Other analysts, including Deutsche Bank, BMO Capital, and RBC Capital, also increased their targets on the stock.

MRK stock jumped 2% as positive clinical trial results for its oncology portfolio drove retail interest and attracted Wall Street optimism. The Phase 3 INTerpath-001 trial showed that a personalized neoantigen therapy significantly improved recurrence-free and distant metastasis-free survival in patients with high-risk melanoma.

SCHW stock gained more than 2% after the company posted growth in core net new assets in July and announced an expansion of its workforce at its India-based global capability centre. The financial services firm also reported record revenue and adjusted earnings per share in its Q2 report.